GtreeBNT

Oct 28, 2020

RegeneRx Joint Venture Enrolls Last Subject in Phase 3 Dry Eye Trial

Feb 03, 2020

RegeneRx Partner Updates on Phase 3 Dry Eye Trial

Oct 16, 2019

RegeneRx JV Partner Updates on Strategic Dry Eye Discussions

May 12, 2019

ReGenTree Initiates ARISE-3 (Phase 3) Trial for Dry Eye Syndrome

Feb 12, 2019

RegeneRx's U.S. Joint Venture Initiates Key Phase 3 Dry Eye Clinical Trial with RGN-259

Jan 04, 2019

RegeneRx Update on Dry Eye and EB Clinical Trials

Oct 29, 2018

RegeneRx Partner Updates on Clinical Trials

Aug 02, 2018

RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa

Apr 25, 2018

GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

Aug 31, 2017

RegeneRx Completes License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia